Espérance de vie à la naissance h/f (années): 46/49


Espérance de vie en bonne santé à la naissance h/f (années, 2003): 35/36


Quotient de mortalité infanto-juvénile (pour 1000 naissances vivantes): 204


Quotient de mortalité 15-60 ans h/f (pour 1000): 483/376


Dépenses totales consacrées à la santé par habitant ($ int., 2005): 86


Dépenses totales consacrées à la santé en % du PIB (2005): 6.7

Burkina Faso
Indicator Value (year)
Births attended by skilled health personnel (%) ? 54.0 (2006)


  Last update: 26 August 2008
Next overall update: July 2009
Immunization Profile - Burkina Faso    
Development status: Least developed GNI / capita (US$):1 440 Infant (under 12 months) mortality rate:2§ 105
GDP / capita (US$):1 1'130 Child (under 5 years) mortality rate:2§ 182
Données démographiques (en milliers)  2
  2007 2006 2005 2004 2003 2000 1990 1980
Population totale 14'784 14'359 13'933 13'507 13'082 11'882 8'871 6'827
Naissance en vie 654 641 628 614 600 560 436 338
Naissances viables 586 573 561 548 535 497 382 293
Population < 5 ans 2'670 2'605 2'541 2'478 2'416 2'240 1'693 1'309
Population < 15 ans 6'776 6'603 6'431 6'261 6'092 5'603 4'221 3'246
Femmes de 15 à 49 ans 3'387 3'280 3'173 3'066 2'958 2'656 1'922 1'437
 
Percent of target population vaccinated, by antigen Hovering over an antigen reveals its fuller definition 
  Last coverage survey 3   Official country estimates 4
  (Click for full official coverage time series from 1980 for Burkina Faso)
  Year Result    
BCG 2005 92        MICS 99* 99* 99* 99* 83 80    -    -
DTP1 2005 90        MICS 99* 99* 99* 99* 99* 84    -    -
DTP3 2005 79        MICS 99* 95 96 88 84 57    -    -
HepB1 (birth dose)    -    -    -    -    -    -    -    -    -    -
HepB3    -    - 99* 76    -    -    -    -    -    -
Hib3    -    - 99* 76    -    -    -    -    -    -
JapEnc    -    -    -    -    -    -    -    -    -    -
MCV 2005 75        MICS 94 88 84 78 76 59    -    -
MCV2    -    -    -    -    -    -    -    -    -    -
Pol3 2005 79        MICS 99* 94 94 83 83 57    -    -
TT2plus 2003 40        DHS 89 81 71 65 50    -    -    -
VAD1    -    - 51 99*    -    -    -    -    -    -
YFV    -    - 89 88 84 76 71 56 65    -
  WHO-UNICEF coverage estimates.5
  (Click for full WHO-UNICEF coverage estimates time series from 1980 for Burkina Faso)
 
   
BCG 99 99 99 99 83 80 95    -
DTP1 99 99 99 99 99 84 92    -
DTP3 99 95 96 88 84 57 66    -
HepB3 99 76    -    -    -    -    -    -
Hib3 99 76    -    -    -    -    -    -
MCV 94 88 84 78 76 59 79    -
PAB 80 76 72 69 67 57 55 0
Pol3 99 94 94 83 83 57 66    -
Number of districts in the country 55  
% of coverage reports received at national level
vs number of reports expected 		-  
Proportion of
districts reporting
DTP3 coverage: 		/
|
|
\
Greater or equal to 90% 91
From 80 to 89% 7
From 50 to 79% 2
Lesser than 50% 0
Proportion of districts not reporting DTP3 coverage 0
Immunization Schedule (2007 or latest available) Hovering over an antigen reveals its fuller definition 
Vaccine Schedule
Vaccine Schedule
BCG        birth;  
DTwPHibHep        8, 12, 16 week;  
Measles        9 months;  
OPV        birth; 8, 12, 16 week;  
TT        1st contact pregnancy; +1, +6 months; +1, +2 year;  
YF        9 months;  
Immunization indicators  
Indicator Expected answer 2007 2006 2005 2004 2003 2002
Planning and management
Multi-year plan (MYP) for immunization Oui/No Oui Oui Oui Oui Oui Oui
What years does the MYP cover? number 2006-2010 2006-2010
Is MYP costing included? Oui/No/NA Oui Oui
Broad health sector integration of MYP for immunization? Oui/No/NA Oui Oui
Was there an annual work plan for immunization services? Oui/No Oui Oui Oui Oui Oui Oui
If yes, was costing included Oui/No Oui Oui
% of districts with microplans to raise immunization coverage From 0 to 100% 100 100 100 100 100 100
Year of last inventory of all refrigeration equipment assigned for public immunization services. number 2004 2004
Year last vaccine management assessment conducted. number 2003 2003
 
System performance
Total number of districts in country number 55 55 55 55 53 53
% districts had >=90% DTP3 coverage From 0 to 100% 91 80 76 45 23
% districts had 80-89% DTP3 coverage From 0 to 100% 7 15 22 31 21
% districts had >=80% DTP3 coverage From 0 to 100% 98 95 98 76 43 23
% districts had 50-79% DTP3 From 0 to 100% 2 5 2 24 57 72
% districts had <50% DTP3 coverage From 0 to 100% 0 0 0 0 0 6
% districts not reporting DTP3 From 0 to 100% 0 0 0 0 22
% districts had >=90% MCV1 coverage From 0 to 100% 71 40 35 11 8 2
% districts had 80-89% MCV1 coverage From 0 to 100% 22 47 35 38
% districts had 50-79% MCV1 coverage From 0 to 100% 7 13 31 51 70
% districts had <50% MCV1 coverage From 0 to 100% 0 0 0 0 2
% districts not reporting MCV1 From 0 to 100% 0 0 0 20
% districts had >=90% TT2+ (pw) coverage From 0 to 100% 51 29 5 2 6
% districts had 80-89% TT2+ (pw) coverage From 0 to 100% 27 22
% districts had 50-79% TT2+ (pw) From 0 to 100% 22 49 0 71 51
% districts had <50% TT2+ (pw) coverage From 0 to 100% 0 0 2 20 40
% districts not reporting TT2plus From 0 to 100% 0 0 93 78 3
% of districts had >10% drop-out rates From 0 to 100% 11 16 31 65 89
% of districts with at least one supervisory visit of all health facilities From 0 to 100% 100 100 100 100 100 100
National % wastage for Hib From 0 to 100% 2 6
National % wastage for MCV From 0 to 100% 21 25
Drop-out rate between DTP1 and DTP3 coverage From 0 to 100% 6 7 8 13 19 22
% point difference between HepB3 and DTP3 coverage From 0 to 100% 0 19
% of coverage report received at national level vs number of reports expected From 0 to 100% 100 100 100 100
 
Surveillance
Is there a national case-based measles surveillance system in place? Oui/No/NA Oui Oui
If yes are specimens taken to confirm diagnosis? Oui/No/NA Oui Oui
System with lab. confirmation measuring impact of vaccination against invasive bacterial diseases? Oui/No/NA Oui Oui
 
Vaccine supply
Was there any district with vaccine supply interruption? Oui/No No Oui No No
% of districts supplied with sufficient number of AD syringes From 0 to 100% 100 100 100 100 100 100
 
Safety
Activity workplan for immunization injection safety Oui/No/NA Oui Oui Oui Oui Oui Oui
Activity workplan for waste management Oui/No Oui Oui Oui Oui
Type of injection equipment Ad syringes Oui/No Oui Oui Oui Oui Oui Oui
Type of injection equipment non AD disposables Oui/No No No Oui No Oui
Type of injection equipment Sterilizables Oui/No No No No No
Are safety boxes distributed with all vaccine deliveries Oui/No Oui Oui Oui Oui Oui Oui
Monitoring of adverse events following immunization Oui/No Oui Oui Oui Oui No No
How many were reported? number 2 16 1796
How many were categorized as "serious" adverse events number 2
National policy regarding disposal: Incineration Oui/No Oui Oui Oui Oui Oui Oui
National policy regarding disposal: Open burning Oui/No No Oui Oui Oui Oui
National policy regarding disposal: Burial Oui/No Oui Oui Oui Oui Oui
National policy regarding disposal: Other Oui/No No No No
National policy regarding disposal: No policy Oui/No No No No
 
Finance
Line item in national budget for vaccines Oui/No Oui Oui Oui Oui Oui Oui
Percentage of routine vaccines funded by Government From 0 to 100% 23 17 100 100 25 90
Line item in national budget for injection supply Oui/No Oui Oui Oui Oui Oui Oui
Immunization spend. Financed using Government funds? From 0 to 100% 19 34 34 36 100 100
 
New and under utilized vaccines introduction
Hepatitis B vaccine integrated in routine immunization schedule Oui/Yes [A]/Yes [P]/No Oui Oui No No No No
Hib vaccine integrated in routine immunization schedule? Oui/Yes [P]/No Oui Oui No No No No
Mumps vaccine integrated in routine immunization schedule Oui/No No No No No No No
Pneumococcal vaccine integrated in routine immunization schedule Oui/No No
Rotavirus vaccine integrated in routine immunization schedule Oui/No No
Rubella vaccine integrated in routine immunization schedule Oui/No No No No No No No
 
Maternal and neonatal tetanus (NT) elimination
NT eliminated Oui/No Oui No No No No No
Protection at birth (PAB) against neonatal tetanus From 0 to 100% 99 93 92 50
 
Polio eradication
Confirmed polio number 0 0 0 9 11 1
Non-polio AFP rate number 2.6 2.3 2.3 2.5 2.8 2.5
% adequate specimen From 0 to 100% 93 92 89 82 85 92
 
Vitamin A
Vitamin A deficiency status Subclinical (SC); Clinical (C); Possibility of VAD (NDP); VAD unlikely (NDU) C C C C C C
Were Vitamin A supplements distributed with routine services? Oui/No No No No No No No
Were Vitamin A supplements integrated with campaigns? Oui/No Oui Oui Oui Oui Oui Oui
 
Measles mortality reduction
Measles adequate second opportunity Oui/No Oui Oui Oui Oui Oui Oui
 
Yellow Fever
Member states at risk for Yellow Fever Oui/No Oui Oui Oui Oui Oui Oui
Yellow Fever in schedule Oui/High risk/Partial/No Oui Oui Oui Oui Oui Oui
 
Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
1Source: "The 2008 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
2Source: "World Population Prospects: The 2006 Revision", New York, United Nations, 2007.
3Source: UNICEF/WHO survey database.
4Source: If no official estimate is available, the administrative coverage is reported. * indicates coverage over 99.5%.
5Source: WHO-UNICEF estimates.

Burkina Faso faces a generalized epidemic. The first case of HIV/AIDS was reported in 1986. At the end of 2003, an estimated 300 000 adults and children were living with HIV/AIDS
in Burkina Faso. About 75% of these people are 15–40 years old. In 2002, the median HIV prevalence among women attending antenatal care clinics at five surveillance sites was
estimated to be 4.2%. The Demographic and Health Survey in 2003 reported overall prevalence of 1.8%, with higher rates in urban (3.1%) than in rural (1.0%) areas. There were more
infected women (3.4%) than men (2.7%). An estimated 29 000 adults and children died from AIDS during 2003.
Map Data Source:WHO/UNAIDS Epidemiological Fact Sheets
and the United States Census BureauMap production:Public Health Mapping & GISCommunicable Diseases (CDS)World Health Organization
3. Situation analysis
Epidemic level and trend and gender data
Major vulnerable and affected groups
Policy on HIV testing and treatment
Antiretroviral therapy: first-line drug regimen, cost per person per year
Assessment of overall health sector reponse and capacity
Knowledge of HIV prevention methods (15-24
years)% - female° 2003 15 DHS*
HIV testing and counselling sites: number of
people tested at all sites Dec 2005 171 257
National AIDS
Council
HIV testing and counselling sites: number of
sites Dec 2005 86 National AIDS
Council
Reported condom use at last higher risk sex
(15-24 years)% - male°° 2003 67 DHS*
Reported condom use at last higher risk sex
(15-24 years)% - female°° 2003 54 DHS*
Knowledge of HIV prevention methods (15-24
years)% - male° 2003 23 DHS*
Estimated number of people living with
HIV/AIDS (0-49 years) 2003
190 000 -

470 000 WHO/UNAIDS
Adult prevalence of HIV/AIDS (15-49 years) 2003
2.7 -

6.5% WHO/UNAIDS
Estimated number of people needing
antiretroviral therapy (0-49 years), 2005
Dec 2005 34 000 WHO/UNAIDS
Reported number of people receiving
antiretroviral therapy (0-49 years), 2005
Dec 2005 8 214 WHO/UNAIDS
2. HIV